{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Placebo", "query": { "intervention": "Placebo: Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32988, "total_pages": 3299, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T00:14:03.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06932263", "title": "Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Tozorakimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 540, "start_date": "2025-03-26", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 64, "location_summary": "Bakersfield, California • Huntington Beach, California • La Mesa, California + 60 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06932263" }, { "nct_id": "NCT00949663", "title": "Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide (GIP)", "type": "DRUG" }, { "name": "Xenin-25", "type": "DRUG" }, { "name": "Glucose-dependent Insulinotropic Polypeptide plus Xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2009-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-07-22", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949663" }, { "nct_id": "NCT03635099", "title": "This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo (fasted)", "type": "DRUG" }, { "name": "BI 25 mg (fasted)", "type": "DRUG" }, { "name": "BI 50 mg (fasted)", "type": "DRUG" }, { "name": "BI 100 mg (fasted)", "type": "DRUG" }, { "name": "BI 200 mg (fasted)", "type": "DRUG" }, { "name": "Placebo (fed)", "type": "DRUG" }, { "name": "BI 400 mg once daily (fed)", "type": "DRUG" }, { "name": "BI 200 mg twice daily, 400 mg total (fed)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 274, "start_date": "2018-09-17", "completion_date": "2021-05-26", "has_results": true, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Alpharetta", "state": "Georgia" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635099" }, { "nct_id": "NCT04350593", "title": "Dapagliflozin in Respiratory Failure in Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Dapagliflozin 10 milligram (mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint Luke's Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1250, "start_date": "2020-04-22", "completion_date": "2021-06-11", "has_results": true, "last_update_posted_date": "2022-06-10", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 22, "location_summary": "Fairhope, Alabama • Miami, Florida • Evanston, Illinois + 18 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04350593" }, { "nct_id": "NCT02290821", "title": "Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Blunt Soft Tissue Injuries/Contusions" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 215, "start_date": "2014-12", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 10, "location_summary": "Bradenton, Florida • Port Orange, Florida • Boise, Idaho + 7 more", "locations": [ { "city": "Bradenton", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02290821" }, { "nct_id": "NCT05813847", "title": "Herniorrhaphy for Postoperative Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hernia, Inguinal", "Post Operative Pain" ], "interventions": [ { "name": "local anaesthetic injection of CPL-01", "type": "DRUG" }, { "name": "Morphine (rescue medication)", "type": "DRUG" }, { "name": "Acetaminophen (rescue medication)", "type": "DRUG" }, { "name": "Oxycodone (rescue medication)", "type": "DRUG" }, { "name": "local anaesthetic injection of placebo", "type": "DRUG" }, { "name": "local anaesthetic injection of ropivacaine HCl", "type": "DRUG" }, { "name": "Open inguinal hernia repair", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Cali Pharmaceuticals LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 518, "start_date": "2023-04-18", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05813847" }, { "nct_id": "NCT01683747", "title": "Single Dose Enteral Tranexamic Acid in Critically Ill Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Shock", "Sepsis", "Hypotension", "Critical Illness" ], "interventions": [ { "name": "Tranexamic Acid", "type": "DRUG" }, { "name": "Control Intervention (Carrier fluid only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "San Diego Veterans Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2012-06", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683747" }, { "nct_id": "NCT01302938", "title": "Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Overactive Bladder" ], "interventions": [ { "name": "Tolterodine ER", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2011-03", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01302938" }, { "nct_id": "NCT01632358", "title": "Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dyslipidaemia" ], "interventions": [ { "name": "TAP311 capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 279, "start_date": "2012-06", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-12-02", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 1, "location_summary": "Miramar, Florida", "locations": [ { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632358" }, { "nct_id": "NCT03204955", "title": "A Low ChloridE hyperTonic Solution for Brain Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Subarachnoid Hemorrhage", "Acute Kidney Injury" ], "interventions": [ { "name": "Sodium chloride /sodium acetate (16.4%)", "type": "DRUG" }, { "name": "Sodium chloride (23.4%)", "type": "DRUG" }, { "name": "PlasmaLyte", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2017-06-28", "completion_date": "2018-09-30", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-09-29T00:14:03.332Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03204955" } ] }